Compare GMEX & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GMEX | PRFX |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | Australia | Israel |
| Employees | 16 | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 1.6M |
| IPO Year | 2023 | 2020 |
| Metric | GMEX | PRFX |
|---|---|---|
| Price | $1.93 | $1.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 4.5M | 33.9K |
| Earning Date | 04-17-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $0.58 |
| 52 Week High | $2.50 | $3.71 |
| Indicator | GMEX | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 60.83 | 26.03 |
| Support Level | $1.44 | $1.26 |
| Resistance Level | $2.10 | $1.58 |
| Average True Range (ATR) | 0.30 | 0.12 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 44.18 | 26.43 |
GMEX Robotics Corp is engaged in the design and deployment of AI-powered robotics and intelligent consumer technologies. The group operates in three business areas: Consumer and Commercial Robotics: Developing intuitive and interactive robots designed to assist with daily tasks, provide smart home integration, and offer new levels of convenience and connectivity to boost productivity; AI-Driven Hardware: Embedding artificial intelligence into physical products to create self-learning and adaptive user experiences; and Innovation & Ecosystem: Building a robust ecosystem of robotic products that communicate and evolve, powered by proprietary AI algorithms.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasise reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the Company's lead product, is based on the local anaesthetic ropivacaine and targets the postoperative pain relief market.